HP Helmerich and Payne Inc

Helmerich & Payne recently saw a significant insider stock sale by the Chairman of the Board, Hans Helmerich, amounting to US$2.1m. Although this sale represented a small portion of his total holding, the overall insider activity over the past year shows more selling than buying. While the company maintains solid insider ownership at 4.3%, this selling trend suggests caution regarding the stock.

Helmerich & Payne's Chairman of the Board recently sold a significant amount of stock, though it represented a small percentage of his total holdings. Over the past year, insider selling has outpaced buying, raising some caution despite the company's relatively high insider ownership. Investors should consider these transactions in their overall assessment of the stock.

Wedge Capital Management L L P NC significantly reduced its stake in Helmerich & Payne, Inc. by 26.5% during the third quarter of 2025. This sell-off involved 70,075 shares, leaving the firm with 193,973 shares valued at approximately $4.285 million. Additionally, Helmerich & Payne's director, Hans Helmerich, sold 75,000 shares for $2.11 million, reducing his position by 13.12%, while the company also missed Q3 EPS estimates despite a 45.8% revenue increase.

Helmerich & Payne (NYSE:HP) Director Hans Helmerich sold 75,000 shares for $2,109,000, representing a 13.12% reduction in his stake. The company recently announced a quarterly dividend of $0.25 per share, and while it missed EPS consensus in its last quarterly earnings, revenue increased by 45.8% year-over-year. Analysts maintain a "Hold" rating for the stock with a consensus price target of $31.20.

Helmerich & Payne (HP) has garnered renewed investor interest following analyst upgrades, driven by deleveraging plans, tighter capital expenditure, and anticipated growth in Saudi drilling demand. While the stock has seen a 36.03% gain over three months, its year-to-date performance remains negative, and a 1-year total shareholder return of -3.98% indicates a slow recovery in sentiment. The article explores contrasting valuation perspectives, with one narrative suggesting it's 2.7% overvalued based on a $27.20 fair value, and another based on a DCF model indicating it's significantly undervalued by approximately 54% at $61.12.

Barclays has reiterated its Overweight recommendation for Helmerich & Payne (HP) on December 17, 2025. Analysts project a median one-year price target of $28.36/share, suggesting a slight upside of 1.24% from its latest closing price. Institutional ownership in Helmerich & Payne has seen a decrease in the number of funds reporting positions, although the average portfolio weight dedicated to HP has increased.